AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00876096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Catch of blood then PCR
Description: To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
Study NCT01976546 — intervention group
Intervention type: DEVICE
Intervention: Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps
Description: Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
Study NCT03414203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
Study NCT03414203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
Study NCT03414203 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
Study NCT01441947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Part of combination arm
Study NCT01441947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: part of combination arm
Study NCT02665663 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: medical device
Study NCT02473094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825mg/m2 bid, D1-D5 q7d
Study NCT02473094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825mg/m2 bid, D1-D5 q7d
Study NCT02473094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin up to 2500mg/d
Study NCT02473094 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3D radiotherapy 50,4Gy divided in 25 fractions
Study NCT02473094 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: 3D radiotherapy 50,4Gy divided in 25 fractions
Study NCT02473094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo up to 2500mg/d
Study NCT03092999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg tablet, single dose, oral administration
Study NCT01221623 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study NCT01221623 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study NCT04031898 — intervention group
Intervention type: OTHER
Intervention: Non Interventional
Description: This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
Study NCT04550208 — intervention group
Intervention type: OTHER
Intervention: 3D analysis of different landing tasks
Description: General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
Study NCT04185545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus RV3 Vaccine (Bio Farma)
Description: Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains > 5x10\^6 fcfu/mL rotavirus vaccine strain RV3
Study NCT04185545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each 1 mL dose of placebo contains 30% of sucrose in DMEM
Study NCT03421665 — intervention group
Intervention type: DEVICE
Intervention: Titan 3D Wedge System
Description: Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
Study NCT00294437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
Study NCT02458040 — intervention group
Intervention type: DRUG
Intervention: Drug selected in the study
Study NCT03618498 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ILM flaps insertion techniques or free ILM flaps.
Description: The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
Study NCT03672669 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Platelet Rich Fibrin (A-PRF)
Description: blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
Study NCT03672669 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte- and platelet-rich fibrin (L-PRF)
Description: blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
Study NCT01847079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Procalcitonin
Description: Procalcitonin to guide obtaining bloodcultures
Study NCT02082028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGStar
Study NCT02082028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glucose meter
Study NCT04227210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine MV-012-968 (dosage #1)
Description: Single dose administered intranasally on Day 1
Study NCT04227210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine MV-012-968 (dosage #2)
Description: Single dose administered intranasally on Day 1
Study NCT02130570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Model Intensive Discharge Intervention
Description: 1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information
Study NCT02004210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial radioembolization (TARE)
Description: transarterial radioembolization
Study NCT02004210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Description: transarterial chemoembolization
Study NCT04982809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone, Dexamethasone, Prednisolone
Description: Corticosteroids
Study NCT02840942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Robot
Description: Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills.
Study NCT02840942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-coping Robot
Description: Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only.
Study NCT00861692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: argatroban
Study NCT03450343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral azacitidine
Description: Azacitidine can be taken with or without food at the same time every day.
Study NCT03450343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-ICE
Description: R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
Study NCT03644225 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measurment with Aspirational Medical Device
Description: The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
Study NCT03644225 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measurment with Cutometer MPA 580
Description: The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
Study NCT01063062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous infusion every 4 weeks.
Study NCT01063062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: methotrexate as per standard of care in clinical practice.
Study NCT03137680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Exercise
Description: Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
Study NCT00136695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg QD
Study NCT00136695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anastrozole
Description: 1 mg QD
Study NCT02195700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
Study NCT04564937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510A
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
Study NCT01348503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Escalating doses starting at 15 mg by mouth per day.
Study NCT01348503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Fixed dose of 400 mg by mouth twice a day.
Study NCT03424863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Muscle Strengthening
Description: 1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
Study NCT02195700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice daily for 12 weeks.
Study NCT03626064 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Counselling
Description: One on one smoking cessation counselling with a certified mental health nurse
Study NCT03626064 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Replacement Therapy
Description: Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
Study NCT01320852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: All patients will have a PET scan as part of their pre-transplant assessment
Study NCT01320852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PET Scan
Description: All patients will have a PET scan as part of their pre-transplant assessment
Study NCT02297711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total ExtraPeritoneal
Description: This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
Study NCT02297711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open minimal suture repair
Description: This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
Study NCT04307368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: 8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
Study NCT04307368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elimination-rotational diet
Description: During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
Study NCT04307368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic diet
Description: 8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
Study NCT02997696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4474
Study NCT02997696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ONO-4474
Study NCT02107625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet A i.e. Low FODMAP diet
Study NCT02107625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet B, i.e. Traditional IBS diet
Study NCT03042650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Referral Intervention Group
Description: The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
Study NCT03042650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice Facilitated Group
Description: The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
Study NCT03404063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac Drug
Description: Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group.
Study NCT03404063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Study NCT01186887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
Study NCT01186887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
Study NCT01802580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Survey
Study NCT01299740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participation in DBT Skills Group
Description: Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
Study NCT01299740 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Treatment as usual
Study NCT03447704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085
Description: 120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
Study NCT03447704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
Study NCT01802580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinonide 0.05% ointment
Study NCT02471118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Description: Adalimumab will be self-administered via subcutaneous (SC) injection
Study NCT04332146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program (MBI-p-R)
Description: The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
Study NCT04332146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booklet-based psychoeducation
Description: The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ vaccine
Description: rMenB+OMV NZ vaccine was administered intramuscularly.
Study NCT02471118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered via subcutaneous (SC) injection
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ vaccine
Description: rMenB+OMV NZ vaccine was administered intramuscularly.
Study NCT04502693 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: MenACWY vaccine was administered intramuscularly.
Study NCT04502693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Description: MenACWY vaccine was administered intramuscularly.
Study NCT04502693 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered intramuscularly.